Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer.
about
Profile of neratinib and its potential in the treatment of breast cancerCIViC databaseCombining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancerQuantitative Phosphoproteomics Analysis of ERBB3/ERBB4 Signaling.The Therapeutic Challenge of Targeting HER2 in Endometrial CancerProteolytic cleavage, trafficking, and functions of nuclear receptor tyrosine kinases.Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidencePreclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer.CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients.Human epidermal growth factor receptor 4 (HER4) is a favorable prognostic marker of breast cancer: a systematic review and meta-analysis.The role of neratinib in HER2-driven breast cancer.Long term storage in liquid nitrogen leads to only minor phenotypic and gene expression changes in the mammary carcinoma model cell line BT474.Linc00152 Functions as a Competing Endogenous RNA to Confer Oxaliplatin Resistance and Holds Prognostic Values in Colon Cancer.Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations.The Tyrosine Kinome Dictates Breast Cancer Heterogeneity and Therapeutic Responsiveness.Clinical significance of overexpression of NRG1 and its receptors, HER3 and HER4, in gastric cancer patients.Human epidermal growth factor receptor 4 (Her4) Suppresses p53 Protein via Targeting the MDMX-MDM2 Protein Complex: IMPLICATION OF A NOVEL MDMX SER-314 PHOSPHOSITE.A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer.HER4 isoform CYT2 and its ligand NRG1III are expressed at high levels in human colorectal cancer.The HER4-YAP1 axis promotes trastuzumab resistance in HER2-positive gastric cancer by inducing epithelial and mesenchymal transition.Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.Novel treatment strategies for patients with HER2-positive breast cancer who do not benefit from current targeted therapy drugs
P2860
Q27012540-80CB490A-4B46-4808-944C-0AB95FF804ACQ27612411-DA58C6C1-C9E5-4D78-91C5-189594C7C309Q35742383-136DA572-99AC-4AB7-9AAD-359853B0DF08Q35888647-633659F5-2604-4FEE-8B00-678761C36B0EQ36064912-51227864-AB16-47E5-BA12-382A08323FBAQ36113481-2D8F2459-8F74-4C18-9359-4E9DDC88A0D8Q36250585-5C8451A3-E673-4B46-AA63-08D04C51AECEQ37109776-5644716C-273D-4F2C-A024-592CBCC4D932Q37685449-391FC02D-0E64-4DF2-8DB6-497371BD8EE3Q37718269-77190CC4-A626-4C83-84B6-D911D3D06B04Q38664492-BEA9E61E-79CF-4600-998B-2C0868AB744BQ38708001-FD258729-D8D2-4584-8CB7-5352C3AB1058Q38740450-119935C9-035E-4C84-A12F-6FC3A207DCA9Q38861026-5E8BCF66-20DE-46FF-B7A4-9BE0E1941724Q38890318-B5ED0A32-5857-42A2-8C60-0617A0367E18Q40176588-F8CD9FEF-C2BB-4412-BA78-D816CA44CB97Q45358927-093C3AF2-C5D2-4CA7-8C14-4B5AD92802EBQ47158524-70F2F8E2-15FC-45F4-936F-203F6F35AD8BQ52608458-739D1ED1-BCAE-4F61-B8B3-DF68001172DEQ52657273-218F894A-C2A7-4AC8-9499-D1D59AD2F375Q55479657-879C1D2C-3DC7-47FD-BA5B-FFED65A409F0Q57106864-A5D7CF23-0742-4501-B30E-39CA027E572E
P2860
Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer.
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Nuclear HER4 mediates acquired ...... n HER2 positive breast cancer.
@ast
Nuclear HER4 mediates acquired ...... n HER2 positive breast cancer.
@en
Nuclear HER4 mediates acquired ...... n HER2 positive breast cancer.
@nl
type
label
Nuclear HER4 mediates acquired ...... n HER2 positive breast cancer.
@ast
Nuclear HER4 mediates acquired ...... n HER2 positive breast cancer.
@en
Nuclear HER4 mediates acquired ...... n HER2 positive breast cancer.
@nl
altLabel
Nuclear HER4 mediates acquired ...... in HER2 positive breast cancer
@en
prefLabel
Nuclear HER4 mediates acquired ...... n HER2 positive breast cancer.
@ast
Nuclear HER4 mediates acquired ...... n HER2 positive breast cancer.
@en
Nuclear HER4 mediates acquired ...... n HER2 positive breast cancer.
@nl
P2093
P2860
P356
P1433
P1476
Nuclear HER4 mediates acquired ...... n HER2 positive breast cancer.
@en
P2093
Anthony Kong
Carla Strina
Daniele Andreis
Daniele Generali
Esther Bridges
Gabriela Kramer-Marek
Jacek Capala
Ji-Liang Li
Mariarosa Cappelletti
Merel Gijsen
P2860
P304
P356
10.18632/ONCOTARGET.1904
P407
P577
2014-08-15T00:00:00Z